SCLX

SEC source: 0000950170-23-052259 · ownership.xml · derivative · entry 1

Ji Henry · CIK 0001470981 · Director · Executive Chairperson

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 200,000

Underlying: Common Stock · 200,000 shares

Expires 2033-10-04

F1 · derivative.exercise_date: 1/48th of the shares subject to the option shall vest on a monthly basis following the grant date, subject to the Reporting Person's continued service to the Issuer through each such vesting date.

SEC source: 0000950170-23-052257 · ownership.xml · derivative · entry 1

SHAH JAISIM · CIK 0001242133 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 200,000

Underlying: Common Stock · 200,000 shares

Expires 2033-10-04

F1 · derivative.exercise_date: 1/48th of the shares subject to the option shall vest on a monthly basis following the grant date, subject to the Reporting Person's continued service to the Issuer through each such vesting date.

SEC source: 0000950170-23-052256 · ownership.xml · derivative · entry 1

Wu Yue Alexander · CIK 0001682419 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 250,000

Underlying: Common Stock · 250,000 shares

Expires 2033-10-04

F1 · derivative.exercise_date: 1/48th of the shares subject to the option shall vest on a monthly basis following the grant date, subject to the Reporting Person's continued service to the Issuer through each such vesting date.

SEC source: 0000950170-23-052255 · ownership.xml · derivative · entry 1

Chun Jay · CIK 0001994406 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 250,000

Underlying: Common Stock · 250,000 shares

Expires 2033-10-04

F1 · derivative.exercise_date: 1/48th of the shares subject to the option shall vest on a monthly basis following the grant date, subject to the Reporting Person's continued service to the Issuer through each such vesting date.

SEC source: 0000950170-23-052254 · ownership.xml · derivative · entry 1

Ma Stephen Hoi · CIK 0001954364 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 150,000

Underlying: Common Stock · 150,000 shares

Expires 2033-10-04

F1 · derivative.exercise_date: 1/48th of the shares subject to the option shall vest on a monthly basis following the grant date, subject to the Reporting Person's continued service to the Issuer through each such vesting date.

SEC source: 0001104659-23-103527 · tm2326753-1_4.xml · derivative · entry 2

Sorrento Therapeutics, Inc. · CIK 0000850261 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 4,490,617 shares

Expires 2027-11-10

F1 · price: Pursuant to that certain Stock Purchase Agreement, dated September 21, 2023, between the Reporting Person and Scilex Holding Company ("Scilex"), Scilex purchased the following securities from the Reporting Person for an aggregate purchase price of (a) $10 million in cash; plus (b) the assumption by Scilex of $100 million of debt under the Reporting Person's non-amortizing super-priority senior secured debtor-in-possession term loan facility; plus (c) the assumption by Scilex of certain obligations of the Reporting Person for legal fees and expenses in the amount of approximately $12.25 million; plus (d) a credit bid of approximately $23 million owed to Scilex under the Reporting Person's non-amortizing super-priority junior secured term loan facility: (i) 60,068,585 shares of Common Stock of Scilex; (ii) 29,057,097 shares of Series A Preferred Stock of Scilex; and (iii) warrants exercisable for 4,490,617 shares of Common Stock of Scilex.

SEC source: 0001104659-23-103527 · tm2326753-1_4.xml · nonDerivative · entry 1

Sorrento Therapeutics, Inc. · CIK 0000850261 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,917,210

F1 · price: Pursuant to that certain Stock Purchase Agreement, dated September 21, 2023, between the Reporting Person and Scilex Holding Company ("Scilex"), Scilex purchased the following securities from the Reporting Person for an aggregate purchase price of (a) $10 million in cash; plus (b) the assumption by Scilex of $100 million of debt under the Reporting Person's non-amortizing super-priority senior secured debtor-in-possession term loan facility; plus (c) the assumption by Scilex of certain obligations of the Reporting Person for legal fees and expenses in the amount of approximately $12.25 million; plus (d) a credit bid of approximately $23 million owed to Scilex under the Reporting Person's non-amortizing super-priority junior secured term loan facility: (i) 60,068,585 shares of Common Stock of Scilex; (ii) 29,057,097 shares of Series A Preferred Stock of Scilex; and (iii) warrants exercisable for 4,490,617 shares of Common Stock of Scilex.

SEC source: 0000899243-23-009127 · doc4.xml · nonDerivative · entry 1

Ji Henry · CIK 0001470981 · Director · Executive Chairperson

10b5-1 filing: No plan indicated

Ownership: Indirect · By BioVintage, Inc.

Disclosed balance after: 2,730

F1 · kind: On December 30, 2022, the Board of Directors of Sorrento Therapeutics, Inc. ("Sorrento") declared a stock dividend (the "Dividend") to all holders of record of its common stock as of the close of business on January 9, 2023, of 0.1410127 of a share of common stock, par value $0.0001 per share, of the Issuer ("Scilex Common Stock") for each one share of common stock, par value $0.0001 per share, of Sorrento ("Sorrento Common Stock"). The Reporting Person wrote a put option in Sorrento Common Stock on August 26, 2022 (the "Put Option"), which was adjusted as a result of the Stock Dividend to relate to an aggregate of 19,500 shares of Sorrento Common Stock and 2,730 shares of Scilex Common Stock and to reflect a corresponding change to the exercise price of the Put Option to $0.80268 per share of Sorrento Common Stock and $8.6002 per share of Scilex Common Stock.

F2 · kind: (continued from footnote 1) The Put Option settled on March 17, 2023 and resulted in the Reporting Person acquiring 2,730 shares of Scilex Common Stock at a price of $8.6002 per share of Scilex Common Stock, in addition to 19,500 shares of Sorrento Common Stock at a price of $0.80268 per share of Sorrento Common Stock.

SEC source: 0000899243-23-002368 · doc4.xml · nonDerivative · entry 1

Sorrento Therapeutics, Inc. · CIK 0000850261 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 61,985,795

F1 · kind: On January 19, 2023, the Reporting Person paid its previously announced stock dividend (the "Dividend") consisting of an aggregate of 75,999,853 shares of common stock of Scilex Holding Company held by the Reporting Person (the "Dividend Shares") to record holders of the Reporting Person's common stock and certain warrants to purchase the Reporting Person's common stock as of January 9, 2023 (the "Record Date"). An aggregate of 2,259,058 Dividend Shares are being held in abeyance by the Reporting Person for the benefit of certain holders of warrants to purchase shares of common stock of the Reporting Person who may be entitled to such shares pursuant to the terms of the applicable warrants following the exercise of such warrants, and at the time such shares are distributed to the applicable warrantholders, the Reporting Person will file a Form 4 reporting such distribution.

F2 · kind: (Continued form footnote 1) The Reporting Person distributed 0.1410127 of a share of the Issuer's common stock for each share of the Reporting Person's common stock outstanding as of the close of business on the Record Date. The stock ratio was calculated by dividing 76,000,000 by the number of shares of the Reporting Person's common stock and warrants to purchase shares of the Reporting Person's common stock outstanding on the Record Date. No fractional shares were issued in connection with the Dividend and the equityholders of the Reporting Person who were entitled to receive fractional shares of the Dividend Stock received cash (without interest) in lieu of such fractional shares.

F1 · shares: On January 19, 2023, the Reporting Person paid its previously announced stock dividend (the "Dividend") consisting of an aggregate of 75,999,853 shares of common stock of Scilex Holding Company held by the Reporting Person (the "Dividend Shares") to record holders of the Reporting Person's common stock and certain warrants to purchase the Reporting Person's common stock as of January 9, 2023 (the "Record Date"). An aggregate of 2,259,058 Dividend Shares are being held in abeyance by the Reporting Person for the benefit of certain holders of warrants to purchase shares of common stock of the Reporting Person who may be entitled to such shares pursuant to the terms of the applicable warrants following the exercise of such warrants, and at the time such shares are distributed to the applicable warrantholders, the Reporting Person will file a Form 4 reporting such distribution.

F2 · shares: (Continued form footnote 1) The Reporting Person distributed 0.1410127 of a share of the Issuer's common stock for each share of the Reporting Person's common stock outstanding as of the close of business on the Record Date. The stock ratio was calculated by dividing 76,000,000 by the number of shares of the Reporting Person's common stock and warrants to purchase shares of the Reporting Person's common stock outstanding on the Record Date. No fractional shares were issued in connection with the Dividend and the equityholders of the Reporting Person who were entitled to receive fractional shares of the Dividend Stock received cash (without interest) in lieu of such fractional shares.

SEC source: 0000899243-23-001880 · doc4.xml · derivative · entry 1

Lee Tien-Li · CIK 0001940120 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 250,000

Underlying: Common Stock · 250,000 shares

Expires 2033-01-17

F1 · derivative.exercise_date: 1/48th of the shares subject to the option shall vest on a monthly basis following the grant date, subject to the Reporting Party's continued service to the Issuer through each such vesting date.

SEC source: 0000899243-23-001866 · doc4.xml · derivative · entry 1

Ji Henry · CIK 0001470981 · Director · Executive Chairperson

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,000,000

Underlying: Common Stock · 9,000,000 shares

Expires 2033-01-17

F1 · derivative.exercise_date: 1/48th of the shares subject to the option shall vest on a monthly basis following the grant date, subject to the Reporting Party's continued service to the Issuer through each such vesting date.

SEC source: 0000899243-23-001870 · doc4.xml · derivative · entry 1

CZEREPAK ELIZABETH · CIK 0001263500 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 350,000

Underlying: Common Stock · 350,000 shares

Expires 2033-01-17

F1 · derivative.exercise_date: 1/48th of the shares subject to the option shall vest on a monthly basis following the grant date, subject to the Reporting Party's continued service to the Issuer through each such vesting date.

SEC source: 0000899243-23-001869 · doc4.xml · derivative · entry 1

SHAH JAISIM · CIK 0001242133 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,700,000

Underlying: Common Stock · 1,700,000 shares

Expires 2033-01-17

F1 · derivative.exercise_date: 1/48th of the shares subject to the option shall vest on a monthly basis following the grant date, subject to the Reporting Party's continued service to the Issuer through each such vesting date.

SEC source: 0000899243-23-001882 · doc4.xml · derivative · entry 1

Thompson Tommy G · CIK 0001324863 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 250,000

Underlying: Common Stock · 250,000 shares

Expires 2033-01-17

F1 · derivative.exercise_date: 1/48th of the shares subject to the option shall vest on a monthly basis following the grant date, subject to the Reporting Party's continued service to the Issuer through each such vesting date.

SEC source: 0000899243-23-001877 · doc4.xml · derivative · entry 1

Hamill Laura · CIK 0001751804 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 250,000

Underlying: Common Stock · 250,000 shares

Expires 2033-01-17

F1 · derivative.exercise_date: 1/48th of the shares subject to the option shall vest on a monthly basis following the grant date, subject to the Reporting Party's continued service to the Issuer through each such vesting date.

SEC source: 0000899243-23-001884 · doc4.xml · derivative · entry 1

Followwill Dorman · CIK 0001717947 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 250,000

Underlying: Common Stock · 250,000 shares

Expires 2033-01-17

F1 · derivative.exercise_date: 1/48th of the shares subject to the option shall vest on a monthly basis following the grant date, subject to the Reporting Party's continued service to the Issuer through each such vesting date.

SEC source: 0000899243-23-001872 · doc4.xml · derivative · entry 1

Lemus David · CIK 0001717972 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 250,000

Underlying: Common Stock · 250,000 shares

Expires 2033-01-17

F1 · derivative.exercise_date: 1/48th of the subject to the option shall vest on a monthly basis following the grant date, subject to the Reporting Party's continued service to the Issuer through each such vesting date.

SEC source: 0000899243-22-037521 · doc4.xml · derivative · entry 1

Sorrento Therapeutics, Inc. · CIK 0000850261 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,490,617

Underlying: Common Stock · 224,841 shares

Expires 2027-11-10

F1 · price: The price reported in Column 8 is a weighted average price. These warrants were purchased in multiple transactions at prices ranging from $0.32 to $0.36 per warrant, inclusive. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or a securityholder of the Issuer, full information regarding the number of warrants purchased at each separate price.

SEC source: 0000899243-22-037015 · doc4.xml · derivative · entry 1

Sorrento Therapeutics, Inc. · CIK 0000850261 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,265,776

Underlying: Common Stock · 46,172 shares

Expires 2027-11-10

F1 · price: The price reported in Column 8 is a weighted average price. These warrants were purchased in multiple transactions at prices ranging from $0.37 to $0.45 per warrant, inclusive. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or a securityholder of the Issuer, full information regarding the number of warrants purchased at each separate price.

SEC source: 0000899243-22-036956 · doc4.xml · derivative · entry 1

Sorrento Therapeutics, Inc. · CIK 0000850261 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,219,604

Underlying: Common Stock · 442,829 shares

Expires 2027-11-10

F1 · price: The price reported in Column 8 is a weighted average price. These warrants were purchased in multiple transactions at prices ranging from $0.2444 to $0.45 per warrant, inclusive. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or a securityholder of the Issuer, full information regarding the number of warrants purchased at each separate price.

SEC source: 0000899243-22-036807 · doc4.xml · derivative · entry 1

Sorrento Therapeutics, Inc. · CIK 0000850261 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,776,775

Underlying: Common Stock · 672,775 shares

Expires 2027-11-10

F1 · price: The price reported in Column 8 is a weighted average price. These warrants were purchased in multiple transactions at prices ranging from $0.13 to $0.28 per warrant, inclusive. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or a securityholder of the Issuer, full information regarding the number of warrants purchased at each separate price.

SEC source: 0000899243-22-035922 · doc4.xml · derivative · entry 2

Sorrento Therapeutics, Inc. · CIK 0000850261 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,104,000

Underlying: Common Stock · 307,296 shares

Expires 2027-11-10

F2 · kind: Reflects the assignment and transfer of the warrant to the Reporting Person by Vickers Venture Fund VI (Plan) Ltd ("Sponsor Two" and together with Sponsor One, the "Sponsors") pursuant the Warrant Transfer Agreement (as described below).

F3 · price: Pursuant to the warrant transfer agreement, dated as of October 12, 2022 (the "Warrant Transfer Agreement"), by and among the Reporting Person, the Sponsors, Vickers Vantage Corp. I ("Vickers") and Maxim Group LLC, Sponsor One transferred 2,796,704 warrant an aggregate of 3,104,000 warrants to the Reporting Person as over 90% of the public Vickers ordinary shares outstanding as of March 17, 2022 were redeemed in connection with the business combination as further described in Vickers' final prospectus and definitive proxy statement, dated October 28, 2022 (the "Proxy Statement/Prospectus") and filed with the Securities and Exchange Commission. The Warrant Transfer Agreement was entered into as consideration for the Reporting Person entering into a letter agreement with Scilex Holding Company ("Scilex") pursuant to which the Reporting Party would fund a loan to Scilex upon its request in the maximum aggregate amount of $10,000,000, as further described in the Proxy Statement/Prospectus.

SEC source: 0000899243-22-035922 · doc4.xml · derivative · entry 1

Sorrento Therapeutics, Inc. · CIK 0000850261 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,796,704

Underlying: Common Stock · 2,796,704 shares

Expires 2027-11-10

F1 · kind: Reflects the assignment and transfer of the warrant to the Reporting Person by Vickers Venture Fund VI Pte Ltd ("Sponsor One") pursuant the Warrant Transfer Agreement (as described below).

F3 · price: Pursuant to the warrant transfer agreement, dated as of October 12, 2022 (the "Warrant Transfer Agreement"), by and among the Reporting Person, the Sponsors, Vickers Vantage Corp. I ("Vickers") and Maxim Group LLC, Sponsor One transferred 2,796,704 warrant an aggregate of 3,104,000 warrants to the Reporting Person as over 90% of the public Vickers ordinary shares outstanding as of March 17, 2022 were redeemed in connection with the business combination as further described in Vickers' final prospectus and definitive proxy statement, dated October 28, 2022 (the "Proxy Statement/Prospectus") and filed with the Securities and Exchange Commission. The Warrant Transfer Agreement was entered into as consideration for the Reporting Person entering into a letter agreement with Scilex Holding Company ("Scilex") pursuant to which the Reporting Party would fund a loan to Scilex upon its request in the maximum aggregate amount of $10,000,000, as further described in the Proxy Statement/Prospectus.

SEC source: 0001104659-22-119278 · tm2229408-1_4seq1.xml · derivative · entry 2

Vickers Venture Fund VI Pte Ltd · CIK 0001839162 · 10% owner · See footnote (1)

Vickers Venture Fund VI (Plan) Pte Ltd · CIK 0001839160 · See footnote (1)

Chi Jeffrey · CIK 0001839163 · See footnote (1)

Ho Chris · CIK 0001838628 · See footnote (1)

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Vickeres Venture Fund VI (Plan) Pte Ltd

Disclosed balance after: 99,000

Underlying: Common Stock · 578,160 shares

Expires 2027-11-10

F1 · kind: Effective November 10, 2022, Vickers Venture Fund VI Pte Ltd and Vickers Venture Fund VI (Plan) Pte Ltd (and indirectly by its managing members, Jeffrey Chi, the Issuer's Chief Executive Officer, and Christopher Ho, the Issuer's Chief Financial Officer) are no longer 10% Holders of Vickers Vantage Corp. I

F2 · kind: In connection with the business combination between Scilex Holding Company (f/k/a Vickers Vantage Corp. I) with Scilex, Inc. (f/k/a Scilex Holding Company, (i) Vickers Venture Fund VI Pte Ltd forfeited 2,465,136 warrants to purchase common shares of Scilex Holding Company ("New Scilex Warrants") and transferred 2,796,704 New Scilex Warrants to to Sorrento Therapeutics, Inc. ("Sorrento") and (ii) Vickers Venture Fund VI (Plan) Pte Ltd forfeited 270,864 New Scilex Warrants and transferred 307,296 to Sorrento. Following such transfers and the forfeitures (i) Vickers Venture Fund VI Pte Ltd holds 901,000 New Scilex Warrants and (ii) Vickers Venture Fund VI (Plan) Pte Ltd holds 99,000 New Scilex Warrants.

F2 · price: In connection with the business combination between Scilex Holding Company (f/k/a Vickers Vantage Corp. I) with Scilex, Inc. (f/k/a Scilex Holding Company, (i) Vickers Venture Fund VI Pte Ltd forfeited 2,465,136 warrants to purchase common shares of Scilex Holding Company ("New Scilex Warrants") and transferred 2,796,704 New Scilex Warrants to to Sorrento Therapeutics, Inc. ("Sorrento") and (ii) Vickers Venture Fund VI (Plan) Pte Ltd forfeited 270,864 New Scilex Warrants and transferred 307,296 to Sorrento. Following such transfers and the forfeitures (i) Vickers Venture Fund VI Pte Ltd holds 901,000 New Scilex Warrants and (ii) Vickers Venture Fund VI (Plan) Pte Ltd holds 99,000 New Scilex Warrants.

SEC source: 0001104659-22-119278 · tm2229408-1_4seq1.xml · derivative · entry 1

Vickers Venture Fund VI Pte Ltd · CIK 0001839162 · 10% owner · See footnote (1)

Vickers Venture Fund VI (Plan) Pte Ltd · CIK 0001839160 · See footnote (1)

Chi Jeffrey · CIK 0001839163 · See footnote (1)

Ho Chris · CIK 0001838628 · See footnote (1)

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Vickers Venture Fund VI Pte Ltd

Disclosed balance after: 901,000

Underlying: Common Stock · 5,261,840 shares

Expires 2027-11-10

F1 · kind: Effective November 10, 2022, Vickers Venture Fund VI Pte Ltd and Vickers Venture Fund VI (Plan) Pte Ltd (and indirectly by its managing members, Jeffrey Chi, the Issuer's Chief Executive Officer, and Christopher Ho, the Issuer's Chief Financial Officer) are no longer 10% Holders of Vickers Vantage Corp. I

F2 · kind: In connection with the business combination between Scilex Holding Company (f/k/a Vickers Vantage Corp. I) with Scilex, Inc. (f/k/a Scilex Holding Company, (i) Vickers Venture Fund VI Pte Ltd forfeited 2,465,136 warrants to purchase common shares of Scilex Holding Company ("New Scilex Warrants") and transferred 2,796,704 New Scilex Warrants to to Sorrento Therapeutics, Inc. ("Sorrento") and (ii) Vickers Venture Fund VI (Plan) Pte Ltd forfeited 270,864 New Scilex Warrants and transferred 307,296 to Sorrento. Following such transfers and the forfeitures (i) Vickers Venture Fund VI Pte Ltd holds 901,000 New Scilex Warrants and (ii) Vickers Venture Fund VI (Plan) Pte Ltd holds 99,000 New Scilex Warrants.

F2 · price: In connection with the business combination between Scilex Holding Company (f/k/a Vickers Vantage Corp. I) with Scilex, Inc. (f/k/a Scilex Holding Company, (i) Vickers Venture Fund VI Pte Ltd forfeited 2,465,136 warrants to purchase common shares of Scilex Holding Company ("New Scilex Warrants") and transferred 2,796,704 New Scilex Warrants to to Sorrento Therapeutics, Inc. ("Sorrento") and (ii) Vickers Venture Fund VI (Plan) Pte Ltd forfeited 270,864 New Scilex Warrants and transferred 307,296 to Sorrento. Following such transfers and the forfeitures (i) Vickers Venture Fund VI Pte Ltd holds 901,000 New Scilex Warrants and (ii) Vickers Venture Fund VI (Plan) Pte Ltd holds 99,000 New Scilex Warrants.